Crohn's disease arthritis treated with infliximab: An open trial in four patients

Michael H. Ellman*, Stephen Hanauer, Michael Sitrin, Russell Cohen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

25 Scopus citations

Abstract

Four patients with Crohn's disease arthritis, who were unresponsive to conventional treatment, improved very rapidly and safely with the use of infliximab, the chimeric antibody directed against tumor necrosis factor alpha. The patients were able to stop or significantly decrease other antirheumatic medications after the infliximab infusions. It is likely that tumor necrosis factor plays a major role in the arthritis as well as the bowel involvement that is seen in Crohn's disease. Suppression of this cytokine may effectively ameliorate Crohn's disease arthritis in some patients.

Original languageEnglish (US)
Pages (from-to)67-71
Number of pages5
JournalJournal of Clinical Rheumatology
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2001

Keywords

  • Crohn's disease arthritis
  • Infliximab

ASJC Scopus subject areas

  • Rheumatology

Fingerprint Dive into the research topics of 'Crohn's disease arthritis treated with infliximab: An open trial in four patients'. Together they form a unique fingerprint.

Cite this